Ronald Blue Trust, Inc. Day One Biopharmaceuticals, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.68 Billion
- Q1 2025
A detailed history of Ronald Blue Trust, Inc. transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 44 shares of DAWN stock, worth $342. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44Holding current value
$342% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
177Shares Held
75.4MCall Options Held
140KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$50 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$45.5 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$44.8 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$37.9 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$35.3 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $572M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...